SEARCH

SEARCH BY CITATION

References

  • 1
    Vitek L, Carey MC. Enterohepatic cycling of bilirubin as a cause of “black” pigment gallstones in adult life. Eur J Clin Invest 2003; 33: 799810.
  • 2
    Broderick AL, Wittenburg H, Lyons MA, Setchell KD, Hofmann AF, Carey MC. Cystic fibrosis transmembrane conductance regulator gene mutations cause “black” pigment gallstone formation: new insights from mouse models and implications for therapeutic interventions in cystic fibrosis. In: AdlerG, BlumHE, FuchsM, StangeEF, eds. Gallstone Pathogenesis and Treatment. Lancaster: Kluwer Academic Publishers, 2004: 2427.
  • 3
    Angelico M, Gandin C, Canuzzi P, Bertasi S, Cantafora A, De Santis A, et al. Gallstones in cystic fibrosis: a critical reappraisal. HEPATOLOGY 1991; 14: 768775.
  • 4
    Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993; 82: 562565.
  • 5
    Brink MA, Slors JF, Keulemans YC, Mok KS, de Waart DR, Carey MC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 1999; 116: 14201427.
  • 6
    Fevery J, Blanckaert N, Heirwegh KP, Preaux AM, Berthelot P. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest 1977; 60: 970979.
  • 7
    Adachi Y, Yamashita M, Nanno T, Yamamoto T. Proportion of conjugated bilirubin in bile in relation to hepatic bilirubin UDP-glucuronyltransferase activity. Clin Biochem 1990; 23: 131134.
  • 8
    Fevery J, Blanckaert N, Leroy P, Michiels R, Heirwegh KP. Analysis of bilirubins in biological fluids by extraction and thin-layer chromatography of the intact tetrapyrroles: application to bile of patients with Gilbert's syndrome, hemolysis, or cholelithiasis. HEPATOLOGY 1983; 3: 177183.
  • 9
    Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 11711175.
  • 10
    Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. HEPATOLOGY 2000; 32: 792795.
  • 11
    Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589595.
  • 12
    Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, et al. Standards and guidelines for CFTR mutation testing. Genet Med 2002; 4: 379391.
  • 13
    Barker M, Thoenes D, Döhmen H, Friedrichs F, Pfannenstiel C, Heimann G. Prevalence of thrombophilia and catheter-related thrombosis in cystic fibrosis. Pediatr Pulmonol 2004; 39: 156162.
  • 14
    Wahlefeld AW, Herz G, Bernt E. Modification of the Malloy-Evelyn method for a simple, reliable determination of total bilirubin in serum. J Clin Lab Invest 1972; 29( Suppl 126): 11.12.
  • 15
    Jendrassik L, Gróf P. Vereinfachte photometrische Methode zur Bestimmung des Bilirubins. Biochem Zschr 1938; 297: 8189.
  • 16
    De Finetti B. Conziderazioni matematiche sul'ereditarieta mendeliana. Meiron 1926; 6: 341.
  • 17
    Del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999; 94: 22592262.
  • 18
    Chaar V, Keclard L, Diara JP, Leturdu C, Elion J, Krishnamoorthy R, et al. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia. Haematologica 2005; 90: 188199.
  • 19
    Premawardhena A, Fisher CA, Fathiu F, de Silva S, Perera W, Peto TE, et al. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet 2001; 357: 19451946.
  • 20
    Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2000; 2: CD000222.
  • 21
    Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. HEPATOLOGY 2002; 36: 525531.
  • 22
    Méndez-Sánchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology 1998; 115: 722732.
  • 23
    Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. HEPATOLOGY 2005; 42: 13911398.